{"entity":{"id":"paper-lutetium-177-vipivotide-tetrax-prostate-journal-2023","kind":"paper","name":"Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments","aka":[],"tldr":"Review on Lutetium-177 vipivotide tetraxetan in Prostate cancer, in Journal not given (2023), one of the most cited Europe PMC records with Lutetium-177 vipivotide tetraxetan in its title.","summary":"Europe PMC indexes no abstract for this record; the title is the only text available.\n\nIndexed on Europe PMC as PubMed record 40209019. Its title names Lutetium-177 vipivotide tetraxetan and its text names Prostate cancer; PubMed types it as a review (Review). It was matched automatically to the idea \"Alpha-emitting PSMA therapy at first metastatic diagnosis\" and no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/40209019/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/40209019"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Journal not given","year":2023,"pmid":"40209019","authors":"Authors not listed","paperType":"review","findings":[],"whatItMeans":"One of the most cited reviews Europe PMC returns for Lutetium-177 vipivotide tetraxetan in Prostate cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.","caveats":["Matched by Lutetium-177 vipivotide tetraxetan in the title and Prostate cancer in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.","A review summarises other studies; the primary reports it cites are the evidence."]},"route":"/key-papers/paper-lutetium-177-vipivotide-tetrax-prostate-journal-2023/","neighbours":{"idea":[{"id":"idea-alpha-first-mhspc","kind":"idea","name":"Alpha-emitting PSMA therapy at first metastatic diagnosis","route":"/ideas/idea-alpha-first-mhspc/"},{"id":"idea-total-body-pet-dosimetry","kind":"idea","name":"Total-body PET for personalised radioligand dosing","route":"/ideas/idea-total-body-pet-dosimetry/"}]}}